Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-14
2005-06-14
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S382000, C514S383000, C514S384000, C514S459000, C514S460000, C546S207000, C549S416000, C549S419000, C548S252000, C548S263200, C548S268800
Reexamination Certificate
active
06906085
ABSTRACT:
The present invention relates compounds of the formula (I):wherein R1, R2, R3, R4, R5, R6, R7and R8represent a variety of substituents; and pharmaceutically acceptable salts thereof. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.
REFERENCES:
patent: WO 0056727 (2000-09-01), None
Chemical Abstracts Service, vol. 70, No. 25, Jun. 23, 1969, Y. Kai, M. Shimizu: “Phenolic constituents fromCryptomeria joaponicawood, V. Structure of hydroxysugiresinol” vol. 14, No. 8, 1986, pp. 430-433.
Castro Pineiro Jose Luis
Raubo Piotr Antoni
Swain Christopher John
Dentz Bernard
Merck Sharp & Dohme Ltd.
Thies J. Eric
Winokur Melvin
LandOfFree
Tetrahydropyran derivatives as neurokinin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydropyran derivatives as neurokinin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydropyran derivatives as neurokinin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3458437